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Summary 
The causal agent(s) and molecular mechanisms of Alzheimer’s disease (AD) remain 
unclear. Mounting evidence suggests that HSV-1 infection is involved in the AD 
pathogenesis. Oxidative stress (OS) may also be crucial in the AD development. Our 
group previously reported that both HSV-1 and OS trigger the appearance of AD-type 
neurodegeneration markers. The main aim of the present study was to identify the 
mechanisms involved in this triggering. Expression studies revealed the involvement of 
a set of OS-regulated genes in HSV-1-infected cells, and in cells harboring the APPswe 
mutation. Functional annotation of these genes revealed the lysosome system to be 
impaired, suggesting that the interaction of OS with both HSV-1 and APP mutations 
affects lysosomal function. Functional studies revealed HSV-1 infection and OS to 
increase the lysosome load, reduce the activity of lysosomal hydrolases, affect cathepsin 
maturation and inhibit the endocytosis-mediated degradation of the EGF receptor. These 
findings suggest alterations in the lysosome system to be involved in different forms of 
AD.  
 
 
Keywords: HSV-1 infection; lysosome; neurodegeneration; microarrays; Alzheimer´s disease   
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1. Introduction 
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease, and is that 
with the highest incidence in the human population aged 65 and over. It causes 
progressive loss of memory and cognitive deterioration, irreversibly leading to 
dementia. Unfortunately, the pathogenic mechanisms involved in cognitive impairment 
and the eventual development of AD remain poorly understood. There is increasing 
evidence that chronic or latent infections of the central nervous system are involved in 
the neurodegenerative process, either via a direct effect of the infectious agents 
themselves or via the associated inflammatory response, or both (Harris and Harris, 
2015; Itzhaki et al., 2016).  
Numerous experimental findings suggest the implication of HSV-1 infection in AD 
pathogenesis (Piacentini et al., 2014). The first evidence of its involvement came from 
epidemiological studies showing that people who have HSV-1 DNA in the brain and 
who also carried the apolipoprotein E type 4 allele were at higher risk of developing AD 
(Itzhaki et al., 1997). Certainly, HSV-1 DNA is present in a high proportion of elderly 
AD brains, usually located within the amyloid plaques (Wozniak et al., 2009). 
Subsequent studies revealed that HSV-1 caused the accumulation of Aβ and 
phosphorylated tau in cell cultures (Lerchundi et al., 2011; Piacentini et al., 2015; 
Wozniak et al., 2007) and in mice (Martin et al., 2014; Zambrano et al., 2008), and 
antiviral treatment of HSV-1-infected cells greatly decreased this accumulation 
(Wozniak et al., 2013; Wozniak et al., 2011).  Moreover, HSV infection, revealed by 
seropositivity, has been significantly associated with development of AD (Letenneur et 
al., 2008; Lovheim et al., 2015a; Lovheim et al., 2015b; Mancuso et al., 2014). Finally, 
the data gathered in genome-wide association studies (GWAS) involving thousands of 
patients with AD and controls identified a set of AD-linked gene variants that seem to 
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increase susceptibility to viral infection of the brain, particularly HSV-1 infection 
(Porcellini et al., 2010). A growing number of studies also point to oxidative stress (OS) 
as key in the pathogenesis of neurodegenerative diseases (Kim et al., 2015). OS has 
been shown to play a prominent role in the progression of AD and contribute towards 
the generation of Aβ deposits and neurofibrillary tangles (Cai et al., 2011). Our group 
has devoted several years to the development and study of neuronal models that 
simulate different aspects of pathogenesis, such as HSV-1 infection and OS. With this 
strategy, we have shown that HSV-1 is able to trigger the neurodegenerative process, 
inducing the appearance of the characteristic markers of AD-type neurodegeneration 
(Alvarez et al., 2012; Santana et al., 2012a; Santana et al., 2012b). In addition, OS has 
been found to strongly disturb cholesterol biosynthesis (Recuero et al., 2009) and APP 
metabolism/processing (Recuero et al., 2013)—processes that are altered in AD brains.  
Lysosomes are the main digestive compartments within cells, and form part of two 
major cellular degradative pathways: autophagy and endocytosis. In recent years, 
substantial links between AD pathogenesis and lysosomal biology have been reported 
(Whyte et al., 2017). Neuron survival requires the continuous recycling of cellular 
materials released by the machineries of autophagy and endocytosis, but neurons are 
particularly vulnerable to disruption of the lysosome system. Indeed, the lysosomal 
storage diseases (LSDs)—a group of some 50 metabolic disorders that arise from 
inherited mutations causing the deficiency of a protein required for proper lysosomal 
function (Filocamo and Morrone, 2011), and which are associated with the 
accumulation of lysosomes and autophagic vesicles—cause severe neurodegenerative 
phenotypes. In fact, given the extensive autophagic-endocytic-lysosomal 
neuropathology seen in the early stages of certain neurodegenerative processes, some 
authors postulate that these, and particularly AD, should be included among the LSDs 
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(Nixon et al., 2008; Wolfe et al., 2013). The enlargement of endosomal compartments, 
perturbed trafficking of lysosomal enzymes, progressive accumulation of autophagic 
vesicles and deficits of lysosomal function are all well-recognized as early 
neuropathological markers of sporadic AD (Neefjes and van der Kant, 2014; Peric and 
Annaert, 2015). Together, these findings support the idea that alterations in lysosomal 
function might contribute significantly to the neurodegeneration associated with AD.  
Our group has reported risk polymorphisms in candidate genes related to HSV-1 
infection (Bullido et al., 2007; Bullido et al., 2008) and the response to OS (Recuero et 
al., 2009), supporting the idea that the latter challenges contribute towards the 
pathogenesis of AD. We have also reported HSV-1 infection and OS to interact and 
promote the appearance of AD-like neurodegeneration events in neuronal cell models 
(Santana et al., 2013). The aim of present work was to determine, via differential gene 
expression in whole genome microarrays, which genes/pathways are important in the 
neurodegeneration induced by HSV-1 and OS. Functional genomic analysis of these 
models revealed the lysosome system to be the main system altered, while functional 
studies indicated HSV-1 and OS to severely affect the lysosome load and lysosomal 
activity. These findings suggest that lysosomal dysfunction plays an important role in 
the AD-like phenotype induced by HSV-1 and OS in neuronal cell models and perhaps 
in clinical AD. 
 
2. Materials and Methods 
2.1. Drugs and antibodies 
Epidermal growth factor (EGF) was purchased from Calbiochem, xanthine and 
bafilomycin A1 were purchased from Sigma. Xanthine oxidase and leupeptin were 
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obtained from Roche and 4’, 6-diamidino-2-phenylindole (DAPI) and ammonium 
chloride from Merck. The antibodies used in this work were: rabbit anti-EGF receptor 
(EGFR) (1005) (Santa Cruz Biotech; sc-03), anti-human CD63, anti-LAMP1 and anti-
human LAMP2 (Developmental Studies Hybridoma Bank, University of Iowa; H5C6, 
H4A3 and H4B4, respectively), rabbit anti-cathepsin B (FL-339) (Santa Cruz Biotech; 
sc-13985), mouse monoclonal anti-human CD222 (Bio-Legend, clone MEM-238; 
315902), mouse anti-early endosome antigen 1 (EEA1) (BD Biosciences; 610457), and 
mouse monoclonal anti-tubulin (Sigma; clone B-5-1-2; T5168). The secondary 
antibodies used for immunostaining were horseradish peroxidase-coupled anti-mouse 
(Vector; PI-2000) and anti-rabbit (Nordic; GAR/IgG(H+L)/PO) antibodies, and 
antibodies labeled with Alexa Fluor 488 (Thermo Fisher; A-21206) or 555 (Thermo 
Fisher; A-31570). 
2.2. Cell culture 
All cell lines used in this work were purchased from the American Type Culture 
Collection. SK-N-MC human neuroblastoma cells were grown as monolayers in 
minimal Eagle’s medium (MEM) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS; Gibco; 10270-106), 2 mM glutamine and 50 mg/ml gentamicin. SK-N-MC 
cells stably transfected with human wild-type APP695 (SK-APPwt) or mutant APP695 
harboring the Swedish mutation (K670N/M671L) (SK-APPswe) were prepared in-house 
and commercialized by NeuronBio. Vero and HeLa cells were passaged in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% FBS, 2 mM glutamine and 
50 mg/ml gentamicin. All cells were grown at 37ºC in a 5% CO2 atmosphere.  
2.3. Infection conditions and exposure to oxidative stress 
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The wild-type HSV-1 strain KOS 1.1 was propagated and purified from Vero cells as 
previously described (Burgos et al., 2002). SK-N-MC cells seeded in complete MEM at 
70–80% confluency were exposed to HSV-1 at 37ºC for 1 h. Mock infections were 
performed using a virus-free suspension. Unbound virus was removed and the cells 
incubated in complete MEM at 37ºC. Time and multiplicity of infection (moi; expressed 
as plaque-forming units [pfu] per cell) are indicated in each experiment. The infectious 
titers of HSV-1 were determined by plaque assay as previously described (Santana et 
al., 2013). OS was induced through the addition of xanthine (10 µM) and xanthine 
oxidase (50 mU/ml) (X-XOD) to fresh medium. Exposure times are indicated in each 
experiment. In samples exposed to OS and HSV-1, X-XOD was added after the 
adsorption of the virus and maintained until the end of infection. 
2.4. EGF receptor degradation assay 
HeLa cells were cultured in serum-free medium for at least 6 h before the treatments 
with HSV-1 and X-XOD. After HSV-1 adsorption/X-XOD addition, cells were 
incubated with medium containing 2% FBS. To stimulate EGF receptor endocytosis, 
EGF (40 ng/ml) was added at the times indicated in each experiment. Cells were 
collected at various time points and analyzed by Western blotting or 
immunofluorescence. For immunoblotting, cells were lysed in RIPA buffer (50 mM 
Tris-HCl pH 7.5, 1% Triton X-100, 150 mM NaCl, 1 mM EDTA and 0.1% sodium 
deoxycholate) containing a protease inhibitor cocktail (Roche) and incubated for 30 min 
at 4ºC. Lysates were centrifuged at 13,000 g for 15 min at 4ºC. The protein 
concentration of the lysates was quantified using the BCA protein assay (Pierce). Cell 
lysates were mixed with 2 Laemmli buffer, heated for 5 min at 100ºC, and then 
subjected to SDS-PAGE and immunoblotted using an anti-EGFR and an anti-tubulin 
antibody to ensure equal loading. The secondary antibody was conjugated with 
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horseradish-peroxidase and detection performed using the Amersham ECL Western 
Blotting Detection Reagent (GE Healthcare). For immunofluorescence, cells were 
cultured on coverslips, fixed with 4% formaldehyde for 10 min, and incubated with an 
anti-EGFR antibody in combination with either anti-EEA1, anti-CD222 or anti-CD63 
followed by incubation with appropriate Alexa-Fluor-coupled secondary antibodies. 
Cells were counterstained with DAPI to visualize the nuclei. All cells were examined 
using a Zeiss LSM710 confocal microscope equipped with an oil-immersion objective 
running ZEN2010 software (Carl Zeiss Microscopy GmbH). Images were processed 
using Adobe Photoshop CS4. 
2.5. Colocalization analysis 
Colocalization analysis of confocal images stained with EGFR and endolysosomal 
markers (EEA1, CD222 and CD63) was performed with the Image-J 1.51u software. 
Each image was split into red and green channels, and analyzed on an identical-sized 
region of interest (ROI) selected for each channel. A total of 25 cells were analyzed. 
Colocalization was quantified using Pearsons´s correlation coefficients determined with 
the Just another Colocalization Plugin (JaCoP) plugin (Bolte and Cordelieres, 2006).  
 2.6. Quantification of lysosome load 
The lysosome load was determined using the acidotropic probes LysoSensor® Green 
DND-189 (LSG) and LysoTracker® Red DND-99 (LTR) (both from Molecular 
Probes). These probes pass freely through cell membranes and typically concentrate in 
acidic organelles. As a control, cells were exposed to ammonium chloride (20 mM) and 
nutrient starvation; for this, the culture medium was exchanged for Earle’s balanced salt 
solution (EBSS). One hour before the end of treatments, cells were exposed to 0.1 μM 
LSG or 1 μM LTR for 1 h at 37°C in culture medium and then washed with PBS. For 
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LTR, cells were lysed with RIPA buffer for 30 min at 4ºC and the lysates centrifuged at 
13,000 g for 10 min. The protein concentration of the lysates was quantified by the 
BCA method, and fluorescence recorded using a FLUOstar OPTIMA microplate reader 
(BMG LABTECH) (excitation wavelength 560 nm, emission wavelength 590 nm). 
Alternatively, cells were fixed with 2% formaldehyde and the LSG fluorescence emitted 
by 10,000 cells in the FL-1 channel (530/30 nm) quantified using a FACSCalibur flow 
cytometer (BD Biosciences) running with CellQuest Pro software. Data analysis was 
performed using Flow Jo software. 
2.7. Cathepsin activity assays and maturation analysis 
The enzymatic activity of different cathepsins was determined as previously described 
with minor modifications (Porter et al., 2013). Briefly, SK-N-MC cells were lysed for 
30 min at 4°C with shaking in 50 mM sodium acetate (pH 5.5), 0.1 M NaCl, 1 mM 
EDTA, and 0.2% Triton X-100. Lysates were clarified by centrifugation and 
immediately used for determination of proteolytic activity. 25-75 µg of protein from cell 
lysates were incubated for 30 min in the presence of the following fluorogenic 
substrates (all from Enzo Life Sciences): Z-VVR-AMC (P-199; most sensitive substrate 
for cathepsin S; 20 µM), Z-GPR-AMC (P-142; specific for cathepsin K; 20 µM), Z-RR-
AMC (P-137; specific for cathepsin B; 20 µM) and the Cathepsin D/E fluorogenic 
substrate Mca-GKPILFFRLK(Dnp)-D-Arg-NH2 (P-145; 10 µM). The AMC released 
was quantified with a microtiter plate reader (Tecan Trading AG) with excitation at 360 
nm and emission at 430 nm (Z-VVR-AMC, Z-GPR-AMC and Z-RR-AMC), or 320 nm 
and 400 nm (Cathepsin D and E fluorogenic substrate). To analyze the maturation of 
cathepsin B, SK-N-MC cell lysates were obtained as above, except that a protease 
inhibitor cocktail (Roche) was added to the lysis buffer. As a control, cells were 
exposed to ammonium chloride (20 mM) and bafilomycin A1 (100 nM) to induce 
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lysosomal inhibition. Cell lysates were mixed with 2 Laemmli buffer, heated for 5 min 
at 100ºC, and then subjected to SDS-PAGE and immunoblotted using an anti-cathepsin 
B and an anti-tubulin antibody to ensure equal loading. 
2.8. Microarray assay, data pre-processing and data analysis 
Total RNA was obtained from untreated and X-XOD-treated cells (three independent 
culture replicates for each condition) using the High Pure RNA Isolation Kit (Roche). 
 The integrity and quantity were checked using an Agilent Bioanalyzer. The One-Color 
Microarray-Based Gene Expression Analysis Protocol (Agilent Technologies) was used 
to amplify and label RNA. Samples were hybridized on whole human genome 
microarrays 4×44 k (Agilent Technologies). 1.65 µg of Cy3-labeled RNA were 
hybridized for 17 h at 65°C in a hybridization oven (Agilent Technologies) set at 10 
rpm, in a final concentration of 1× GEx Hybridization Buffer HI-RPM (Agilent 
Technologies). The arrays were then washed and dried using a centrifuge according to 
the manufacturer's instructions, and scanned at 5 mm resolution in a DNA Microarray 
Scanner (Agilent Technologies) using the default settings for 4×44 k format one-color 
arrays. Images provided by the scanner were analyzed using Feature Extraction software 
v.10.7.3.1 (Agilent Technologies). Raw signals were threshold to 1 and quantile 
normalization (Bolstad et al., 2003) performed using GeneSpring software. Data were 
expressed on a log2 scale. Of the 41,105 probes present in the chip, those fulfilling the 
following criteria were deemed suitable for further analysis: (i) promoting a signal 
within the higher 80th percentiles in at least 75% of the replicates in one condition; (ii) 
flagging at least 75% of the replicates in a given condition as present or marginal, and 
(iii) showing a coefficient of variation across samples of > 2.5%. Quality control checks 
were based on the bioconductor package ArrayQualityMetrics 
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(www.bioconductor.org). All samples employed for analysis were processed using the 
Limma bioconductor package (Smyth, 2004). For each comparison, genes with a 
Benjamini-Hochberg corrected p-value  0.05 were considered differentially 
expressed (Benjamini and Hochberg, 1995). Unless otherwise stated, each comparison 
focused on the genes differentially expressed and with a change of at least 1.2-fold 
between the compared conditions. Genes that were differentially expressed were 
uploaded to bioinformatic tools for data mining. Gene annotation co-occurrence 
discovery (GeneCodis; genecodis.cnb.csic.es) and ingenuity pathway analysis 
(Ingenuity® Systems, www.ingenuity.com) were used to identify pathways and 
functions significantly over- or underrepresented in the gene lists compared to the 
whole human genome. 
2.9. Quantitative RT-PCR 
The mRNA transcribed from each gene was quantified by two-step reverse transcription 
PCR ([RT]-PCR) using TaqMan low density arrays (Applied Biosystems) as previously 
described (Recuero et al., 2009). Briefly, total RNA isolated from SK-N-MC cells was 
subjected to reverse transcription using the High Capacity cDNA Archive Kit (Applied 
Biosystems). Real-time PCR was then performed in an ABI Prism 7900HT SD® 
(Applied Biosystems) using TaqMan arrays for the following genes: GAPDH - 
Hs02758991_g1; ATP6AP1: Hs00184593_m1; ATP6V1H: Hs00977530_m1; CTSB: 
Hs00947433_m1; CTSF - Hs00186901_m1; LAMP2 - Hs00174474_m1; LIPA - 
Hs01548815_m1; NPC1 - Hs00264835_m1; and NPC2 - Hs00197565_m1. The relative 
quantities in treated and untreated cells were determined by the ΔΔCt method using 
SDS v.2.1.1 software. GAPDH was used as the housekeeping gene, the expression of 
which did not change at any time. 
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2.10. Data analysis 
Data are shown as means  standard error of the mean (SEM). Differences between 
groups were analyzed pairwise using the 2-tailed Student t test. Significance was 
recorded at p<0.05 (*), p<0.01(**), and p<0.001(***). Before analysis, the largest and 
the smallest variances were tested for homogeneity using the F-test. 
 
3. Results 
3.1. Microarray gene expression studies revealed alterations in the lysosome system 
To study the impact of HSV-1 infection and OS on gene expression, and to identify 
putative genes and/or pathways associated with AD, a microarray analysis covering the 
whole human genome was performed for SK-N-MC human neuroblastoma cells. To 
mimic the situation of endogenous infection in AD brains, a cell model of HSV-1 
infection at a low viral dose in the presence of mild OS for 24 and 36 h was established. 
In earlier work, we developed a neuronal cell model of mild oxidative stress using the 
free radical generating system xanthine/xanthine oxidase (X-XOD). This cell model 
allowed the analysis of free radical-induced events preceding cell death. X-XOD 
induced an increase in the production of radical oxygen species (Recuero et al., 2010) 
and in cytosolic calcium levels, finally leading to apoptotic cell death (Recuero et al., 
2009). A cellular model for familial AD (SK-APPswe) was also exposed to OS for 24 
and 36 h. Compared to the respective controls (non-infected SK-N-MC cells and SK-
APPwt cells), a full 833 genes were modulated by OS in the infection cell model, and 
158 genes in the familial AD cell model at 24 h of treatment (Supplementary Figure 1). 
To identify common pathogenic mechanisms for sporadic and familial AD, the focus 
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was set on those genes regulated by OS in both models. This identified 65 genes 
significantly overexpressed (fold change > 1.2) and three significantly repressed (fold 
change < 0.8) for a p-value cut-off of 0.05. The complete list of genes is shown in 
Supplementary Table 1. To study the pathways associated with differently expressed 
genes, Gene Annotation Co-occurrence Discovery (GeneCodis) software was used 
(Carmona-Saez et al., 2007; Nogales-Cadenas et al., 2009; Tabas-Madrid et al., 2012). 
As shown in Table 1, significant enrichment was noted for the Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathway 04142: “Lysosome”. Five genes of the above 
68—cathepsin F (CTSF), lipase A, lysosomal acid, cholesterol esterase (LIPA); ATPase, 
H
+
 transporting, lysosomal accessory protein 1 (ATP6AP1); Niemann-Pick disease, type 
C1 (NPC1); and lysosomal-associated membrane protein 2 (LAMP2)—were annotated 
to the lysosome system in which they have different roles. To confirm the GeneCodis 
results, the same gene list was examined using the Ingenuity Pathway Analysis 
software's core analysis routine (Ingenuity® Systems, www.ingenuity.com). The top 
annotated Diseases & Functions category was “lysosomal storage disease” with a p-
value of 1.42x10
-5
. These results identify the lysosome pathway as the main function 
altered. 
Quantitative RT-PCR was used to verify the expression of eight selected lysosomal 
genes, including the five genes annotated to the lysosome system in the cell models. 
Supplementary Figure 2 shows the expression values obtained at 24 and 36 h when 
modulated by HSV-1 or OS alone, or in combination. All the genes except for CTSB 
were upregulated by X-XOD treatment at 24 h in infected and non-infected cells, 
suggesting that the lysosome system was regulated by OS. Gene expression continued 
to increase at 36 h in non-infected cells. This increase did not appear in infected cells 
suggesting that HSV-1 and OS interact in the regulation of this system. These genes 
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were also overexpressed in the familial cell model in the presence of X-XOD 
(unpublished observations). These results led to the undertaking of a functional analysis 
of this system in the HSV-1 infection model. 
3.2. HSV-1 and OS enhance the lysosome load 
The gene expression microarray data for the OS-treated HSV-1-infected and familial 
AD cellular models revealed the significant upregulation of genes related to the 
lysosome system. The impact of HSV-1 and OS on the lysosome system was therefore 
studied with the aim of investigating the possible alterations induced by these factors. 
Previous work by our group has shown that the greatest effect on neurodegenerative 
events provoked by HSV-1 and OS is achieved with a moi of 10 pfu/cell at 18 h. These 
conditions ensure that almost all cells are infected, and were therefore used in the 
following experiments. 
The effect of HSV-1 and OS on the quantity of lysosomes was first explored. The total 
lysosome load was monitored by using two lysosomotropic probes: LysoSensor Green 
(LSG) and LysoTracker Red (LTR). The intensity of fluorescence of LSG is pH-
dependent and is commonly used to examine lysosomal pH changes. When the effects 
of HSV-1 and OS were examined by FACS analysis, a significant increase in LSG 
staining was observed in the infected cells, independent of their oxidative status (Figure 
1A). To confirm the effect of the treatments on the lysosomal compartment, LTR 
fluorescence was recorded; LTR concentrates in acidic organelles but, unlike LSG, its 
fluorescence intensity is not dependent on pH. Quantification of the LTR fluorescence 
levels confirmed the significant increase in the lysosomal content provoked by HSV-1. 
In this case, OS also caused LTR fluorescence to increase. No synergistic effect was 
seen between HSV-1 infection and OS (Figure 1B). These fluorescence assays were 
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validated using two modulators of lysosomal activity: ammonium chloride (a 
lysosomotropic agent that neutralizes lysosomal pH) and nutrient starvation (a positive 
control to increase lysosomal content) (Figure 1C). The elevation of the fluorescence 
intensity of the lysosomotropic probes induced by HSV-1 and OS indicates an increase 
in the lysosome load. This increase was also evaluated by monitoring the amount of the 
two most abundant proteins in lysosomes—LAMP1 and LAMP2. Both proteins were 
enriched in cells exposed to HSV-1 and X-XOD (Figure 1D), confirming the 
accumulation of lysosomes observed in the experiments with lysosomotropic probes. 
3.3. Lysosomal function is impaired by HSV-1 and OS 
Since cells exposed to HSV-1 and OS showed an increase in their lysosome loads, 
perturbations in lysosomal function and endocytic trafficking were sought by assessing 
the activity and maturation of lysosomal cathepsins and the degradation of EGFR.  
3.3.1. HSV-1 and OS inhibit the activity of lysosomal cathepsins 
The role of HSV-1 infection and OS on lysosomal proteolysis was examined by 
monitoring the enzymatic activity of several lysosomal cathepsins, employing 
fluorogenic substrates specific for cathepsins B (Figure 2A), D/E (Figure 2B), K (Figure 
2C) and S (Figure 2D). All cathepsin activities recorded in SK-N-MC cells grown under 
OS were significantly lower than in control cultures. Similar (though less outstanding) 
results were seen for HSV-1-infected cells, suggesting that both factors trigger a defect 
in the proteolytic activity of lysosomes. No synergistic effect was observed between 
HSV-1 infection and OS. 
Among the lysosomal proteases, cathepsin B has a broad specificity and plays a major 
role in intracellular protein degradation. Cathepsin B is activated by proteolysis in the 
acidified lysosome to produce a mature proteolytic product (Turk et al., 2001). To 
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assess the impact of HSV-1 infection and OS on activation state of this cathepsin, 
immunoblot analysis of cell lysates that have been stabilized by the addition of 
lysosomal inhibitors were performed (Figure 2E). HSV-1 did not affect the mature 
cathepsin B levels, indicating that reduced cathepsin B activity was not due to defects in 
its processing. However, OS induced a significant decrease in the amount of mature 
cathepsin B and a concomitant increase of the procathepsin B levels. Bafilomycin A1 
and ammonium chloride, two agents that neutralize the pH of lysosomes, also blocked 
the maturation of cathepsin B, suggesting that OS could be affecting the lysosome pH. 
In fact, OS is known to cause permeabilization of the lysosomal membrane, thereby 
causing lysosome alkalization (Johansson et al., 2010). These data indicate a different 
nature of lysosomal dysfunction in cells infected with HSV-1 and exposed to OS. 
To confirm that the impairment of the lysosome system also takes place in cells treated 
in the same way as in the microarray experiments, the quantity and functionality of 
lysosomes were determined. Both at 24 and 36 h, cells exposed to HSV-1 and OS (both 
separately and in combination) showed a marked increase in their lysosomal content 
(revealed via increased LTR fluorescence) (Figure 3A) and significantly reduced 
cathepsin B and D/E activity (Figure 3B). 
Taken together, these results confirm that lysosome load and proteolysis are severely 
compromised by HSV-1 infection and OS. 
3.3.2. Lysosomal degradation of EGFR is affected by HSV-1 and OS 
A standard test for assessing receptor-mediated lysosomal degradation is to monitor 
EGFR levels. Upon EGF stimulation, EGFR is internalized by clathrin-mediated 
endocytosis and efficiently degraded by the lysosome system. These experiments were 
performed in HeLa cells since SK-N-MC cells do not express endogenous EGFR (van 
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Weering et al., 1995). Previous studies have shown that the stimulation of HeLa cells 
with EGF can result in up to 80% EGFR degradation (Laketa et al., 2014). These data 
are consistent with those obtained by our group showing a 75% EGFR degradation after 
3 h of EGF treatment (Figure 4A). When the impact of HSV-1 and OS on EGFR 
degradation was studied by Western blot analysis, total EGFR levels remained higher in 
HeLa cells exposed to HSV-1 and OS compared to untreated cells (Figure 4A). These 
results were confirmed by immunofluorescence experiments. In untreated cells, EGFR 
was mainly localized to the plasma membrane and, after the addition of EGF, was 
internalized and rapidly degraded. In contrast, HSV-1 and OS induced a strong increase 
in EGFR intracellular staining (Figure 4B), suggesting both treatments led to a defect in 
EGF-induced EGFR degradation.  
Since EGFR is internalized by the endocytic machinery and then degraded by the 
lysosomes, tests were made to determine whether EGFR accumulation induced by 
HSV-1 and OS takes place in some compartment of this pathway. The distribution of 
EGFR was examined by confocal microscopy analysis using antibodies specific to 
marker proteins of early endosomes (EEA1), late endosomes (insulin-like growth factor 
2 receptor, CD222) and lysosomes (CD63, a lysosomal membrane protein) (Figure 5A). 
Endogenous EGFR was undetectable in untreated cells after 5 hours of EGF stimulation 
(Figure 4B). No significant colocalization of EGFR with early endosomal or lysosomal 
markers was detected in HSV-1-infected cells. However, confocal images revealed 
EGFR to colocalize significantly with CD222 in HSV-1-infected cells independently of 
their oxidative status, indicating an impairment of EGFR trafficking that causes the 
accumulation of EGFR in late endosomes. In contrast, OS induced an increase in the 
colocalization of EGFR and CD63 staining, showing that EGFR is able to reach the 
lysosome in this condition (Figure 5B). 
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To exclude that low levels of colocalization of EGFR and CD63 could result from rapid 
lysosomal degradation of EGFR in infected cells, the confocal analysis was repeated in 
the presence of the lysosomal inhibitors leupeptin and ammonium chloride (Figure 6A). 
In these conditions, no colocalization of CD63 with EGFR was detected, confirming the 
impairment of the transport of EGFR to the lysosomes in cells exposed to HSV-1. In 
contrast, inhibition of lysosomal function caused a huge increase of the lysosomal 
localization of EGFR in untreated cells, and a small but significant increase of the 
lysosomal localization of EGFR in X-XOD-treated cells (Figure 6B). Similar results 
were obtained with the lysosomal inhibitor bafilomycin A1 (unpublished observations). 
These results suggest that only some of the EGFR molecules are degraded by lysosomes 
in cells exposed to OS indicating a defect in the lysosomal degradation.  
 
4. Discussion  
The present results show that HSV-1 infection and OS can induce significant 
defects in the functioning of the lysosome system. These findings are supported by 
those of several GWAS that identify polymorphisms associated with AD to affect 
endocytosis and lipid metabolism (Harold et al., 2009; Jones et al., 2010; Lambert et al., 
2009; Lambert et al., 2013). How the latter contribute to neurodegeneration is under 
intense investigation, but it is already known that some of these variations result in 
abnormal trafficking in the endo-lysosomal and autophagic networks (Cormont et al., 
2003; Moreau et al., 2014). Interestingly, several of these variations—namely APOE, 
ABCA7, CD2AP, and PICALM—have been directly or indirectly associated with the 
herpes simplex life cycle, supporting the involvement of HSV-1 in AD pathogenesis 
(Licastro et al., 2011; Porcellini et al., 2010). The latter authors suggest that these genes 
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(among others) give rise to a genetic signature that might affect the ability of the central 
nervous system to fight herpesvirus infection. These findings agree with the present 
results and together they suggest the lysosome system to be important in AD 
pathogenesis and strengthen the hypothesis that HSV-1 has a causal role in AD.  
Experiments with the lysosomotropic probes LTR and LSG showed the 
significant increase in the lysosome load caused by HSV-1 infection and OS. However, 
while the lysosome load also increased under OS, only the LTR fluorescence increased. 
Unlike LTR, LSG fluorescence is pH-sensitive and may indicate changes in lysosomal 
mass or pH. OS is known to cause the permeabilization of the lysosomal membrane, 
thereby releasing hydrolases from the lysosomal lumen into the cytosol and causing 
lysosome alkalization (Johansson et al., 2010). In this context, a recent report showed 
that sub-lethal OS induces lysosome biogenesis and lysosomal membrane 
permeabilization in rat myoblasts (Leow et al., 2017). Interestingly, increased 
concentrations of lysosomal proteins have been found in the cerebrospinal fluid and 
brains of patients with AD (Armstrong et al., 2014; Barrachina et al., 2006), and the 
accumulation of lysosomes is a well-known hallmark of AD brains (Cataldo et al., 
1995; Cataldo et al., 1996; Gowrishankar et al., 2015). The increase in the lysosome 
load induced by HSV-1 and OS is consistent with the overexpression of lysosomal 
genes and the enhanced amount of the two most abundant lysosomal proteins—LAMP1 
and LAMP2—observed in our cell model of infection and OS. A number of studies 
have shown that upregulation of lysosomal proteins might be involved in protecting 
neurons against toxicity and damage (Bendiske and Bahr, 2003; Hawkes et al., 2006). 
Given the increased lysosome load caused by HSV-1 and OS, the effect of both 
stimuli on lysosomal proteolytic activity was examined. Cathepsins are abundant 
lysosomal endopeptidases that catalyze the hydrolysis of a wide variety of substrates. 
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HSV-1 infection and OS significantly reduced the activity of cathepsins B, K, S, and 
D/E. Numerous examples of the inhibition of lysosomal enzymatic activity by OS have 
been reported (Porter et al., 2013). Importantly, mutations in CTSD cause neuronal 
ceroid lipofuscinosis (NCL) (a human LSD associated with severe mental retardation 
and dementia), and CTSF and D removal in mice lead to a phenotype that resembles 
NCL (Koike et al., 2000; Tang et al., 2006). In addition, inhibition and/or loss of 
cathepsin B and L lead to lysosomal dysfunction and the accumulation of intracellular 
cholesterol and Aβ (Cermak et al., 2016). Finally, there are several reports of reduced 
lysosomal enzyme activity in association with AD (recently reviewed in (Whyte et al., 
2017). These studies indicate the importance of cathepsin activity in maintaining 
lysosomal function and preventing neurodegenerative processes. In conclusion, HSV-1 
and OS appear to induce an increase in the lysosome load that does not correlate with 
any increase in lysosomal enzyme activity. Further, HSV-1 and OS severely impair the 
proteolytic activity of lysosomes. All these findings suggest that the lysosomal defects 
reported in our cell model of infection and OS are not directly related to the alteration of 
lysosomal gene expression. Rather, the upregulation of lysosomal genes could represent 
a protective cell response to increase lysosome biogenesis and therefore enhance the 
degradative capacity of lysosomes. 
The impairment of the endocytic pathway is one of the earliest events in AD 
(Peric and Annaert, 2015). Defects in it have been associated with lysosomal 
dysfunction, and were evaluated in the present cell model. The results revealed the 
accumulation of EGFR in late endosomes in HSV-1-infected cells, indicating 
endosomal trafficking to have been affected by infection. In line with these findings, no 
significant colocalization of EGFR and the lysosomal protein CD63 was observed in 
cells exposed to HSV-1 in the presence of lysosomal inhibitors indicating that EGFR is 
21 
 
unable to reach the lysosome. This endosomal accumulation suggests that the final step 
of this pathway—the fusion of late endosomes with lysosomes—is altered by the virus. 
Along these lines, HSV-1 glycoprotein B has been reported to impair endosomal 
trafficking (Niazy et al., 2017), and we previously described that the fusion of 
lysosomes with autophagosomes was also strongly altered in HSV-1-infected cells 
(Santana et al., 2012a). Thus, neither during endocytosis nor autophagy (which 
converge in the lysosome) can vesicular cargoes be delivered to the lysosomes, causing 
an accumulation of autophagosomes and late endosomes in infected cells. In contrast, 
colocalization of EGFR with lysosomal markers was significantly increased in cells 
exposed to OS, both in the absence and in the presence of lysosomal inhibitors. Thus, 
EGFR is able to reach the lysosome but its degradation is inefficient in cells exposed to 
OS. These results indicate a different nature of lysosomal dysfunction between HSV-1 
and OS conditions. In addition, there are also differences between HSV-1-infected cells 
and cells exposed to OS when analyzing the maturation process of cathepsins. Similar 
to other proteases, cathepsins are synthesized as inactive precursors and, in the acidic 
environment of the lysosome, are activated by proteolytic removal of the N-terminal 
propeptide (Turk et al., 2001). OS strongly blocked the maturation of cathepsin B 
suggesting that lysosome pH could be altered, whereas HSV-1 did not affect the 
maturation process. All of these data suggest that OS cause lysosome alkalization. Since 
lysosomal proteases are optimally active at low pH, the increase in lysosomal pH could 
explain the lysosomal localization of EGFR, the overall decrease in cathepsin activities, 
and the inhibition of the maturation of cathepsin B induced by OS. Additional studies 
are needed to determine the molecular mechanisms behind the lysosomal degradation 
failure occurring in infected cells. 
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Taken together, the present results strongly suggest the involvement of the 
lysosome system in the AD-like phenotype induced by HSV-1 and OS in neuronal cell 
models. Numerous studies support the role of lysosomal dysfunction in 
neurodegeneration, and the enhancement of lysosome efficiency in patients with AD 
might be a therapeutic strategy worth exploring. The stimulation of transcription factor 
EB (TFEB) function—the master regulator of lysosomal biogenesis—has recently been 
suggested to be neuroprotective in different mouse models of neurodegenerative 
diseases (Polito et al., 2014; Xiao et al., 2015). In addition, the genetic deletion of 
cystatins (endogenous inhibitors of cysteine proteases, including several cathepsins) has 
been reported to attenuate amyloidogenesis and improve synaptic and cognitive 
function in AD mouse models (Sun et al., 2008; Yang et al., 2014). 
In summary, HSV-1 and OS increased the lysosome load, reduced the activity of 
different lysosomal hydrolases, and led to defective endocytosis-mediated EGFR 
degradation in a cellular model of AD, suggesting the lysosome system to have been 
impaired. Functional genomic analysis suggested the same. These alterations might 
contribute to neurodegeneration by reducing the degradation of toxic aggregates. 
Lysosomal dysfunction may therefore play a major role in the onset of AD, and 
deserves further exploration. 
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Table 1. Functional annotation of the genes regulated by oxidative stress in cells infected 
with HSV-1 or carrying the APPswe mutation 
Item Code Item Name NG Hyp* Genes 
Kegg:04142 Lysosome 5 6.58E-05 CTSF, NPC1, LIPA, LAMP2, 
ATP6AP1 
GO:0002576 platelet degranulation 3 0.0045 VEGFB, STXBP1, LAMP2 
GO:0007596,  
GO:0030168 
blood coagulation, 
platelet activation 
4 0.0050 VEGFB, PDE1A, LAMP2, SLC8A2 
GO:0006629 lipid metabolic 
process 
4 0.0055 FADS2, LIPA, ACSL4, LIPH 
GO:0007596 blood coagulation 5 0.0066 VEGFB, MAFF, PDE1A, LAMP2, 
SLC8A2 
GO:0006811 ion transport 5 0.0092 SLC22A18, SCN4B, KCNAB2, 
ATP6AP1, SLC8A2 
GO:0001525 angiogenesis 3 0.0097 ANG, MFGE8, FZD5 
GO:0008152 metabolic process 4 0.0098 ANG, UGT3A2, METTL7A, FAP 
The input list (the 68 genes of interest) was compared with the annotated human 
genome (34208 items) to identify KEGG Pathways, Gene Ontology Cellular Functions 
or Gene Ontology Molecular Functions over or underrepresented, using the GeneCodis 
annotation tool (http://genecodis.cnb.csic.es). The resultant items with a corrected p 
value<0.01 and the symbol of the annotated genes are shown. NG = Number of 
annotated genes in the input list; Hyp* = Corrected hypergeometric p value. 
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FIGURE CAPTIONS 
Figure 1. Effect of OS and HSV-1 infection on lysosome load. After HSV-1 infection 
(moi 10) and X-XOD, NH4Cl and starvation treatments, SK-N-MC cells were loaded 
with either LysoSensor Green (LSG) or LysoTracker Red (LTR) for 1 h. (A) LSG 
fluorescence was quantified by flow cytometry in the green spectrum (FL-1 channel). 
(B) LTR fluorescence was recorded using a microplate reader. (C) As a control, cells 
were exposed to NH4Cl and nutrient starvation. In (A) and (B), graphs represent the 
mean  SEM of five experiments, and in (C) the mean  SD of two experiments. Data 
are expressed as the percentage with respect to non-infected cells (mock) (**p<0.01, 
***p<0.001). D) SK-N-MC cells were treated with X-XOD and infected with HSV-1 at 
a moi of 10 pfu/cell for 18 h and Western blot analysis with anti-LAMP1, anti-LAMP2 
and anti-tubulin antibodies were performed. LAMP1 and LAMP2 levels were 
determined by densitometric analysis and the ratio of LAMP proteins to tubulin is 
shown below the blots. Data are the mean of two experiments. 
Figure 2. HSV-1 and OS induce a reduction of lysosomal enzyme activity. SK-N-
MC cells were exposed to HSV-1 (moi 10) and X-XOD for 18 h. The relative 
enzymatic activities (compared with mock-infected cells) of cathepsins B (A), D and E 
(B), K (C) and S (D) were quantified and normalized by the protein content of the 
lysates. Data are the mean  SEM of at least four experiments (**p<0.01, ***p<0.001). 
E) SK-N-MC cells were exposed to HSV-1 (moi 10) and X-XOD or incubated with
bafilomycin A1 (BafA1) or ammonium chloride for 18 h and cathepsin B levels were 
analyzed by Western blot. A tubulin blot is shown as a control for equal loading. 
Procathepsin and mature cathepsin B amount was determined by densitometric analysis 
and the ratio of cathepsin B to tubulin is shown below the blots. Data are the mean of 
two experiments. 
Figure 3. Effect of lower doses of HSV-1 on lysosomal content and cathepsin 
activities. SK-N-MC cells were treated with X-XOD and infected with HSV-1 at a moi 
of 0.1 pfu/cell for 24 or 36 h. A) LysoTracker Red (LTR) fluorescence was quantified 
using a microplate reader. Graphs represent the mean  SD of a representative 
experiment performed in triplicate; data are expressed as a percentage with respect to 
mock-infected cells. B) The relative enzymatic activities, compared with mock-infected 
cells, of cathepsins B and D/E were quantified and normalized by the protein content of 
the lysates. Data are the mean  SEM of three experiments (*p<0.05, **p<0.01, 
***p<0.001). 
Figure 4. HSV-1 and OS impair lysosomal degradation of EGFR. HeLa cells were 
treated with HSV-1 (moi 10) and X-XOD for 13 h and EGFR degradation then 
determined by stimulating the cells with 40 ng/ml EGF for the indicated times to induce 
EGFR internalization. A) Western blot analysis was performed with anti-EGFR and 
anti-tubulin antibodies. EGFR degradation was determined by quantifying the amount 
of remaining EGFR via densitometric analysis and normalized against tubulin. 
Graphical data represent the mean  SEM of three experiments and are expressed as the 
percentage quantity of EGFR present at time t=0 (100%) (*p<0.05, **p<0.01). B) 
Immunofluorescence images of HeLa cells using an anti-EGFR antibody. DAPI-stained 
nuclei are shown. DAPI staining reveals HSV-1 to induce the generation of black 
patches corresponding to chromatin margination. Note the accumulation of EGFR in 
cells exposed to OS and HSV-1. Scale bar: 10 µm. 
Figure 5. Internalized EGFR colocalizes with late endosomal markers in HSV-1-
infected cells. A) HeLa cells were exposed to HSV-1 (moi 10) and X-XOD for 18 h. 5 
h before the end of treatments, HeLa cells were stimulated with 40 ng/ml EGF and the 
colocalization of EGFR with early endosomal (EEA1), late endosomal (CD222), and 
lysosomal (CD63) markers analyzed by confocal microscopy. The yellow color in the 
merged panels indicates colocalization of signals. Scale bar: 5 µm. B) Quantification of 
the colocalization of EGFR and endolysosomal markers. Confocal fluorescence images 
were analyzed as described in Materials and Methods. The graph shows the relative 
colocalization (Pearson´s correlation coefficient). Significance was determined using a 
Student t-test (***p<0.001). 
Figure 6. Colocalization analysis of EGFR with lysosomal markers in the presence 
of lysosomal inhibitors. A) HeLa cells were treated with X-XOD and infected with 
HSV-1 at a moi of 10 pfu/cell for 18 h in the absence or presence of the lysosomal 
inhibitors leupeptin (leu) and ammonium chloride (NH4Cl). 5 h before the end of 
treatments, HeLa cells were stimulated with 40 ng/ml EGF and the colocalization of 
EGFR with the lysosomal marker CD63 analyzed by confocal microscopy. The yellow 
color in the merged panels indicates colocalization of signals. Scale bar: 5 µm. B) 
Quantification of the colocalization of EGFR and CD63 stainings. Confocal 
fluorescence images were analyzed as described in Materials and Methods. The graph 
shows the relative colocalization (Pearson´s correlation coefficient). Significance was 
determined using a Student t-test (**p<0.01; ns: non-significant). 
 
